Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 02:40 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases.